Folger Nolan Fleming Douglas Capital Management Inc. raised its stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 2.9% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 103,223 shares of the medical instruments supplier’s stock after buying an additional 2,945 shares during the period. DENTSPLY SIRONA makes up approximately 1.0% of Folger Nolan Fleming Douglas Capital Management Inc.’s holdings, making the stock its 22nd largest position. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in DENTSPLY SIRONA were worth $6,445,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in XRAY. 1832 Asset Management L.P. raised its position in shares of DENTSPLY SIRONA by 11,745.2% in the third quarter. 1832 Asset Management L.P. now owns 151,500 shares of the medical instruments supplier’s stock worth $9,003,000 after buying an additional 150,221 shares during the period. Highbridge Capital Management LLC increased its position in DENTSPLY SIRONA by 502.7% in the third quarter. Highbridge Capital Management LLC now owns 65,234 shares of the medical instruments supplier’s stock worth $3,877,000 after buying an additional 54,411 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in DENTSPLY SIRONA during the third quarter worth about $13,490,000. Echo Street Capital Management LLC increased its position in DENTSPLY SIRONA by 101.7% in the third quarter. Echo Street Capital Management LLC now owns 461,136 shares of the medical instruments supplier’s stock worth $27,405,000 after buying an additional 232,461 shares in the last quarter. Finally, HighTower Advisors LLC acquired a new position in DENTSPLY SIRONA during the third quarter worth about $565,000. Hedge funds and other institutional investors own 95.29% of the company’s stock.

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Shares of DENTSPLY SIRONA Inc. (XRAY) opened at 63.31 on Friday. The company’s 50-day moving average is $63.20 and its 200 day moving average is $61.02. The stock has a market capitalization of $14.51 billion, a P/E ratio of 40.74 and a beta of 1.25. DENTSPLY SIRONA Inc. has a 52 week low of $55.00 and a 52 week high of $65.83.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Tuesday, May 9th. The medical instruments supplier reported $0.49 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.50 by $0.01. The firm had revenue of $900.50 million during the quarter, compared to the consensus estimate of $916.55 million. DENTSPLY SIRONA had a net margin of 9.42% and a return on equity of 7.37%. The company’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.69 EPS. On average, equities analysts forecast that DENTSPLY SIRONA Inc. will post $2.84 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/06/16/folger-nolan-fleming-douglas-capital-management-inc-has-6-45-million-stake-in-dentsply-sirona-inc-xray-updated-updated.html.

XRAY has been the subject of several recent analyst reports. Goldman Sachs Group, Inc. (The) downgraded shares of DENTSPLY SIRONA from a “neutral” rating to a “sell” rating and lowered their target price for the company from $60.00 to $55.00 in a research note on Tuesday, May 23rd. Zacks Investment Research upgraded shares of DENTSPLY SIRONA from a “sell” rating to a “hold” rating in a research note on Wednesday, April 19th. Cleveland Research raised shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating in a report on Tuesday, May 23rd. Barrington Research cut shares of DENTSPLY SIRONA from an “outperform” rating to a “market perform” rating in a report on Tuesday, February 21st. Finally, BidaskClub cut shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a report on Saturday, June 10th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $66.44.

In other DENTSPLY SIRONA news, CEO James G. Mosch sold 50,600 shares of the company’s stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $63.49, for a total transaction of $3,212,594.00. Following the completion of the sale, the chief executive officer now owns 105,083 shares of the company’s stock, valued at $6,671,719.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Christopher T. Clark sold 89,700 shares of the company’s stock in a transaction that occurred on Friday, April 7th. The stock was sold at an average price of $62.67, for a total value of $5,621,499.00. Following the sale, the chief executive officer now directly owns 112,067 shares of the company’s stock, valued at approximately $7,023,238.89. The disclosure for this sale can be found here. Insiders own 1.99% of the company’s stock.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Receive News & Stock Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related stocks with our FREE daily email newsletter.